MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- AJANTA PHARMA LTD. (pharmaceuticals)
- Latest 8 Quarter Result
AJANTA PHARMA Quarterly Results (AJPH)
Here are the latest quarterly results of AJANTA PHARMA. For more details, see the AJANTA PHARMA financial fact sheet and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
AJANTA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 5,152 | 6,119 | 6,428 | 6,512 | 6,820 | 6,682 | 7,159 | 7,487 | |
| Other income | Rs m | 16 | 76 | 132 | 146 | 567 | 131 | 49 | 55 | |
| Turnover | Rs m | 5,168 | 6,196 | 6,560 | 6,659 | 7,387 | 6,813 | 7,208 | 7,542 | |
| Expenses | Rs m | 3,881 | 4,436 | 4,651 | 4,652 | 5,306 | 4,450 | 4,417 | 5,071 | |
| Gross profit | Rs m | 1,271 | 1,684 | 1,766 | 1,856 | 1,488 | 2,232 | 2,743 | 2,417 | |
| Depreciation | Rs m | 188 | 228 | 233 | 236 | 260 | 280 | 283 | 291 | |
| Interest | Rs m | 8 | 18 | 49 | 16 | 36 | 16 | 15 | 26 | |
| Profit before tax | Rs m | 1,092 | 1,515 | 1,616 | 1,751 | 1,759 | 2,067 | 2,492 | 2,155 | |
| Tax | Rs m | 203 | 368 | 452 | 676 | 467 | 589 | 790 | 388 | |
| Profit after tax | Rs m | 889 | 1,146 | 1,164 | 1,076 | 1,292 | 1,478 | 1,702 | 1,766 | |
| Gross profit margin | % | 24.7 | 27.5 | 27.5 | 28.5 | 21.8 | 33.4 | 38.3 | 32.3 | |
| Effective tax rate | % | 18.6 | 24.3 | 28.0 | 38.6 | 26.6 | 28.5 | 31.7 | 18.0 | |
| Net profit margin | % | 17.3 | 18.7 | 18.1 | 16.5 | 18.9 | 22.1 | 23.8 | 23.6 | |
| Diluted EPS | Rs | 10.1 | 13.0 | 13.2 | 12.2 | 14.7 | 16.8 | 19.4 | 20.1 | |
| Diluted EPS (TTM) | Rs | 44.0 | 45.0 | 44.0 | 48.6 | 53.2 | 56.9 | 63.1 | 70.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: AJANTA PHARMA 3QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: IPCA LABS GLENMARK PHARMA CADILA HEALTHCARE NOVARTIS GSK PHARMA
Compare AJANTA PHARMA With: IPCA LABS GLENMARK PHARMA CADILA HEALTHCARE NOVARTIS GSK PHARMA
Compare AJANTA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)
Indian share markets witnessed selling pressure throughout the day today and ended lower.
Views on news
AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)
Feb 5, 2021 | Updated on Feb 5, 2021For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
What's Behind the Rally in Pharma Stocks? (Views On News)
May 11, 2021The second wave of Covid has given a new lease of life to pharma stocks.
Why Did Alembic Pharma Shares Fall Today? (Views On News)
May 5, 2021Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.
AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
More Views on NewsMost Popular
The Next Smallcap Winners (Profit Hunter)
Apr 30, 2021Price is the only due diligence one might require to buy this business.
Time to Buy Smallcaps? (Fast Profits Daily)
Apr 30, 2021In this video, I'll show you why I favour smallcaps over the Nifty.
Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)
May 6, 2021Why are markets discounting the economic impact of Covid?
My Secret to Find Breakthrough Stocks (Fast Profits Daily)
May 7, 2021I've used this trading technique for many years with great success. I'm sharing it with you today.
MoreOUR TOP 5 IDEAS
- FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
AJANTA PHARMA SHARE PRICE
May 12, 2021 (Close)
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA 5-YR ANALYSIS
COMPARE AJANTA PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.